Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Louis M. Messina is active.

Publication


Featured researches published by Louis M. Messina.


JAMA | 1991

Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group

Marc R. Mayberg; Samuel E. Wilson; Yatsu F; Weiss Dg; Louis M. Messina; Linda A. Hershey; Colling C; Eskridge J; Deykin D; Winn Hr

OBJECTIVE To determine whether carotid endarterectomy provides protection against subsequent cerebral ischemia in men with ischemic symptoms in the distribution of significant (greater than 50%) ipsilateral internal carotid artery stenosis. DESIGN Prospective, randomized, multicenter trial. SETTING Sixteen university-affiliated Veterans Affairs medical centers. PATIENTS Men who presented within 120 days of onset of symptoms that were consistent with transient ischemic attacks, transient monocular blindness, or recent small completed strokes between July 1988 and February 1991. Among 5000 patients screened, 189 individuals were randomized with angiographic internal carotid artery stenosis greater than 50% ipsilateral to the presenting symptoms. Forty-eight eligible patients who refused entry were followed up outside of the trial. OUTCOME MEASURES Cerebral infarction or crescendo transient ischemic attacks in the vascular distribution of the original symptoms or death within 30 days of randomization. INTERVENTION Carotid endarterectomy plus the best medical care (n = 91) vs the best medical care alone (n = 98). RESULTS At a mean follow-up of 11.9 months, there was a significant reduction in stroke or crescendo transient ischemic attacks in patients who received carotid endarterectomy (7.7%) compared with nonsurgical patients (19.4%), or an absolute risk reduction of 11.7% (P = .011). The benefit of surgery was more profound in patients with internal carotid artery stenosis greater than 70% (absolute risk reduction, 17.7%; P = .004). The benefit of surgery was apparent within 2 months after randomization, and only one stroke was noted in the surgical group beyond the 30-day perioperative period. CONCLUSIONS For a selected cohort of men with symptoms of cerebral or retinal ischemia in the distribution of a high-grade internal carotid artery stenosis, carotid endarterectomy can effectively reduce the risk of subsequent ipsilateral cerebral ischemia. The risk of cerebral ischemia in this subgroup of patients is considerably higher than previously estimated.


Circulation | 2011

Predictors of Abdominal Aortic Aneurysm Sac Enlargement After Endovascular Repair

Andres Schanzer; Roy K. Greenberg; Nathanael D. Hevelone; William P. Robinson; Mohammad H. Eslami; Robert J. Goldberg; Louis M. Messina

Background— The majority of infrarenal abdominal aortic aneurysm (AAA) repairs in the United States are performed with endovascular methods. Baseline aortoiliac arterial anatomic characteristics are fundamental criteria for appropriate patient selection for endovascular aortic repair (EVAR) and key determinants of long-term success. We evaluated compliance with anatomic guidelines for EVAR and the relationship between baseline aortoiliac arterial anatomy and post-EVAR AAA sac enlargement. Methods and Results— Patients with pre-EVAR and at least 1 post-EVAR computed tomography scan were identified from the M2S, Inc. imaging database (1999 to 2008). Preoperative baseline aortoiliac anatomic characteristics were reviewed for each patient. Data relating to the specific AAA endovascular device implanted were not available. Therefore, morphological measurements were compared with the most liberal and the most conservative published anatomic guidelines as stated in each manufacturers instructions for use. The primary study outcome was post-EVAR AAA sac enlargement (>5-mm diameter increase). In 10 228 patients undergoing EVAR, 59% had a maximum AAA diameter below the 55-mm threshold at which intervention is recommended over surveillance. Only 42% of patients had anatomy that met the most conservative definition of device instructions for use; 69% met the most liberal definition of device instructions for use. The 5-year post-EVAR rate of AAA sac enlargement was 41%. Independent predictors of AAA sac enlargement included endoleak, age ≥80 years, aortic neck diameter ≥28 mm, aortic neck angle >60°, and common iliac artery diameter >20 mm. Conclusion— In this multicenter observational study, compliance with EVAR device guidelines was low and post-EVAR aneurysm sac enlargement was high, raising concern for long-term risk of aneurysm rupture.


Surgical Clinics of North America | 1997

Visceral artery aneurysms.

Louis M. Messina; Charles J. Shanley

Visceral artery aneurysms are an uncommon form of vascular disease, yet are important to the practicing vascular surgeon because of the potential for rupture or erosion into an adjacent viscus, resulting in life-threatening hemorrhage. Many visceral artery aneurysms still present with rupture, which often results in the death of the patient. An aggressive approach to the diagnosis and management of these aneurysms is warranted. The treatment of visceral artery aneurysms has significantly evolved over the past decade. Open surgical repair has been the standard method of treatment, usually by aneurysm resection or simple ligation. Open surgical repair is durable with excellent long-term results, but is accompanied by the morbidity and mortality of a major abdominal operation. Over the past decade, catheter-based treatments with coil embolization and placement of stent grafts have emerged as promising therapies to treat visceral artery aneurysms. These have provided safe and effective short-term results and should be preferentially used in selected patients at high surgical risk.


Journal of Vascular Surgery | 1995

Variability in measurement of abdominal aortic aneurysms

Frank A. Lederle; Samuel E. Wilson; Gary R. Johnson; Donovan B. Reinke; Fred N. Littooy; Charles W. Acher; Louis M. Messina; David J. Ballard; Howard J. Ansel

PURPOSE The purpose of this study was to report interobserver and intraobserver variability of computed tomography (CT) measurements of abdominal aortic aneurysm (AAA) diameter and agreement between CT and ultrasonography observed in the course of a large, multicenter, randomized trial on the management of small AAAs. METHODS CT measurements of AAA diameter from participating centers were compared with measurements made from the same scan by a central laboratory. Blinded central remeasurement of a randomly selected subset of these CT scans was used to assess intraobserver variability. Agreement between AAA measurements by CT and ultrasonography done within 30 days of each other was also assessed. RESULTS For interobserver pairs of local and central CT measurements of AAA diameter (n = 806), the difference was 0.2 cm or less in 65% of pairs, but 17% differed by at least 0.5 cm. For intraobserver pairs of central CT remeasurements (n = 70), 90% differed by 0.2 cm or less, 70% were within 0.1 cm, and only one differed by 0.5 cm. Of 258 ultrasound-measured and central CT pairs, the difference was 0.2 cm or less in 44% and at least 0.5 cm in 33%. Ultrasound measurements were smaller than central CT measurements by an average of 0.27 cm (p < 0.0001). Local CT and ultrasound measurements showed a marked preference for recording by half centimeter. CONCLUSIONS A high degree of precision is possible in CT measurement of AAA diameter, but this precision may not be obtained in practice because of differences in measurement techniques. Differences between imaging modalities increase variability further. Variations in AAA measurement of 0.5 cm or more are not uncommon, and this should be taken into account in management decisions. Efforts to reduce variation in measurement are warranted and might include (1) seeking agreement between surgeons and radiologists on a precise definition of AAA diameter, (2) limiting the number of radiologists who measure AAAs, and (3) use of calipers and magnifying glass for CT measurements.


Annals of Vascular Surgery | 1996

Common Splanchnic Artery Aneurysms: Splenic, Hepatic, and Celiac

Charles J. Shanley; Nikhil Shah; Louis M. Messina

Aneurysms involving the splanchnic arteries represent an uncommon and potentially lethal form of vascular disease. Because they frequently present as life-threatening clinical emergencies, a clear understanding of the presentation and management of these aneurysms is essential for the practicing vascular surgeon. The purpose of this review was to document recent changes in the diagnosis and management of common splanchnic artery aneurysms. Traditionally the most commonly reported splanchnic artery aneurysms have involved, in decreasing order of frequency, the splenic, hepatic, and celiac arteries.~ We reviewed the English language literature for the past 10 years (1985 to 1995) for reports of these lesions. Interestingly, in contrast to previously published series, aneurysms of the hepatic arteries were the most frequently reported splanchnic artery aneurysms in the past decade. This trend probably relates to the increasing use of percutaneous diagnostic and therapeutic biliary tract procedures. During these procedures, injury to the intrahepatic branches of the hepatic artery can lead to the development of false aneurysms of these vessels. In addition to these iatrogenic false aneurysms, the increased use of diagnostic CT scanning following blunt liver trauma has also led to increased detection of posttraumatic false aneurysms of the intrahepatic arterial


Human Gene Therapy | 2011

Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α1-Antitrypsin: Interim Results

Terence R. Flotte; Bruce C. Trapnell; Margaret Humphries; Brenna Carey; Roberto Calcedo; Farshid N. Rouhani; Martha Campbell-Thompson; Anthony T. Yachnis; Robert A. Sandhaus; Noel G. McElvaney; Christian Mueller; Louis M. Messina; James M. Wilson; Mark L. Brantly; David R. Knop; Guo-jie Ye; Jeffrey D. Chulay

Recombinant adeno-associated virus (rAAV) vectors offer promise for the gene therapy of α(1)-antitrypsin (AAT) deficiency. In our prior trial, an rAAV vector expressing human AAT (rAAV1-CB-hAAT) provided sustained, vector-derived AAT expression for >1 year. In the current phase 2 clinical trial, this same vector, produced by a herpes simplex virus complementation method, was administered to nine AAT-deficient individuals by intramuscular injection at doses of 6.0×10(11), 1.9×10(12), and 6.0×10(12) vector genomes/kg (n=3 subjects/dose). Vector-derived expression of normal (M-type) AAT in serum was dose dependent, peaked on day 30, and persisted for at least 90 days. Vector administration was well tolerated, with only mild injection site reactions and no serious adverse events. Serum creatine kinase was transiently elevated on day 30 in five of six subjects in the two higher dose groups and normalized by day 45. As expected, all subjects developed anti-AAV antibodies and interferon-γ enzyme-linked immunospot responses to AAV peptides, and no subjects developed antibodies to AAT. One subject in the mid-dose group developed T cell responses to a single AAT peptide unassociated with any clinical effects. Muscle biopsies obtained on day 90 showed strong immunostaining for AAT and moderate to marked inflammatory cell infiltrates composed primarily of CD3-reactive T lymphocytes that were primarily of the CD8(+) subtype. These results support the feasibility and safety of AAV gene therapy for AAT deficiency, and indicate that serum levels of vector-derived normal human AAT >20 μg/ml can be achieved. However, further improvements in the design or delivery of rAAV-AAT vectors will be required to achieve therapeutic target serum AAT concentrations.


Journal of Vascular Surgery | 1991

Clinical characteristics and surgical management of vascular complications in patients undergoing cardiac catheterization: Interventional versus diagnostic procedures☆

Louis M. Messina; Thomas W. Wakefield; Gerald B. Zelenock; S. Martin Lindenauer; Lazar J. Greenfield; Lloyd A. Jacobs; Elaine P. Fellows; Susan V. Grube; James C. Stanley

The purpose of this report is to define the clinical characteristics and outcome of surgical management of vascular complications after interventional cardiac catheterization and to contrast them to those after diagnostic cardiac catheterization. From October 1985 to December 1989, 101 patients were treated for 106 vascular complications after 1866 interventional and 5046 diagnostic cardiac catheterizations at the University of Michigan Medical Center. Interventional catheterizations resulted in 69 vascular complications in 64 patients (frequency 3.4%). The most common interventions included coronary angioplasty (34), of which 10 required percutaneous partial cardiopulmonary bypass, intraaortic balloon pump placement (14), and aortic valvuloplasty (11). Interventional catheter-related complications included hemorrhage (33), arterial thrombosis (18), pseudoaneurysm formation (12), catheter embolization (2), thromboembolism (2), as well as arteriovenous fistula, pseudoaneurysm, and arterial dissection (1 each). Fifteen of these 69 patients (24%) had suffered acute myocardial infarction just before their catheterization. Surgical repair was performed under local anesthesia in 70% of patients. Major vascular reconstructions were required in 9% of patients. Three percent of the involved lower extremities had to be amputated because of complications occurring after arterial puncture. Eight percent of the patients incurring vascular complications after interventional procedures died after operation. Diagnostic catheterizations resulted in 37 vascular complications in 37 patients (frequency 0.7%). In contrast to diagnostic cardiac catheterization, vascular complications after interventional cardiac catheterization occurred more frequently, were most often due to hemorrhage at the vascular access site, and occurred in high-risk, critically ill patients.(ABSTRACT TRUNCATED AT 250 WORDS)


Journal of Vascular Surgery | 1997

Relationship of age, gender, race, and body size to infrarenal aortic diameter

Frank A. Lederle; Gary R. Johnson; Samuel E. Wilson; Ian L. Gordon; Edmund P. Chute; Fred N. Littooy; William C. Krupski; Dennis F. Bandyk; Gary W. Barone; Linda M. Graham; Robert J. Hye; Donovan B. Reinke; Louis M. Messina; Charles W. Acher; David J. Ballard; Howard J. Ansel; A. W. Averbook; Michel S. Makaroun; Gregory L. Moneta; Julie A. Freischlag; Raymond G. Makhoul; M. Tabbara; G. B. Zelenock; Joseph H. Rapp

PURPOSE To assess the effects of age, gender, race, and body size on infrarenal aortic diameter (IAD) and to determine expected values for IAD on the basis of these factors. METHODS Veterans aged 50 to 79 years at 15 Department of Veterans Affairs medical centers were invited to undergo ultrasound measurement of IAD and complete a pre-screening questionnaire. We report here on 69,905 subjects who had no previous history of abdominal aortic aneurysm (AAA) and no ultrasound evidence of AAA (defined as IAD > or = 3.0 cm). RESULTS Although age, gender, black race, height, weight, body mass index, and body surface area were associated with IAD by multivariate linear regression (all p < 0.001), the effects were small. Female sex was associated with a 0.14 cm reduction in IAD and black race with a 0.01 cm increase in IAD. A 0.1 cm change in IAD was associated with large changes in the independent variables: 29 years in age, 19 cm or 40 cm in height, 35 kg in weight, 11 kg/m2 in body mass index, and 0.35 m2 in body surface area. Nearly all height-weight groups were within 0.1 cm of the gender means, and the unadjusted gender means differed by only 0.23 cm. The variation among medical centers had more influence on IAD than did the combination of age, gender, race, and body size. CONCLUSIONS Age, gender, race, and body size have statistically significant but small effects on IAD. Use of these parameters to define AAA may not offer sufficient advantage over simpler definitions (such as an IAD > or = 3.0 cm) to be warranted.


Journal of Vascular Surgery | 2003

Modular branched stent graft for endovascular repair of aortic arch aneurysm and dissection

Timothy A.M. Chuter; Darren B. Schneider; Linda M. Reilly; Errol Lobo; Louis M. Messina

PURPOSE We describe a modular stent graft for use in endovascular repair of aneurysms of the aortic arch. METHOD Carotid-carotid and left carotid-subclavian bypass grafts are created surgically. Two large, fully stented grafts are inserted endoluminally. The proximal component is bifurcated, with a wide proximal trunk and two distal limbs, one long and narrow, the other short and wide. This component is inserted through the carotid artery and deployed with the trunk and short wide limb in the ascending thoracic aorta; the long narrow limb opens into the innominate artery. After delivery system removal and carotid artery repair, a distal component is inserted through a femoral approach to bridge the gap between the short, wide distal limb of the proximal component and the nondilated descending thoracic aorta. The result is a branched stent graft, implanted proximally into the ascending aorta and distally into the innominate artery and descending thoracic aorta. CONCLUSION The system has been used successfully to treat a large wide-necked pseudoaneurysm of the aortic arch.


The Lancet | 1997

Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene

Krishnankutty Sudhir; Tony M. Chou; Louis M. Messina; Stuart Hutchison; Kenneth S Korach; Kanu Chatterjee; Gabor M. Rubanyi

1146 Vol 349 • April 19, 1997 hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 1994; 24: 490–94. 3 Kosinski DJ, Grubb BP, Elliott L, Dubois D. Treatment of malignant neurogenic syncope with dual chamber cardiac pacing and fluoxetine hydrochloride. PACE 1995; 18: 1455–57. 4 Grubb BP, Kosinski D, Samoil D, Pothoulakis A, Lorton M, Kip K. Postpartum syncope. PACE 1995; 18: 1028–31. 5 McAnally LE, Threlkeld KR, Dreyling CA. Case report of a syncopal episode associated with fluoxetine. Ann Pharm 1992; 26: 1090–91.

Collaboration


Dive into the Louis M. Messina's collaboration.

Top Co-Authors

Avatar

Andres Schanzer

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Jessica P. Simons

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francesco A. Aiello

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jinglian Yan

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Guodong Tie

University of Massachusetts Amherst

View shared research outputs
Top Co-Authors

Avatar

Elias J. Arous

University of Massachusetts Medical School

View shared research outputs
Researchain Logo
Decentralizing Knowledge